(NEPH) Nephros - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6406714005
NEPH EPS (Earnings per Share)
NEPH Revenue
NEPH: Water Filtration, Ultrafiltration, Biofilm Reduction
Nephros Inc. is a commercial-stage company that specializes in providing innovative water solutions to various markets, including medical, commercial, and industrial sectors in the United States. Their product portfolio includes ultrafiltration systems and water filters designed to remove a wide range of contaminants, such as bacteria, viruses, and heavy metals, from water. The companys products are used in diverse settings, including dialysis centers, hospitals, military facilities, and commercial establishments, to improve water quality and prevent infections. With a strong focus on delivering high-quality products, Nephros has established itself as a reliable player in the water treatment industry.
Analyzing the companys market presence and product offerings, it is evident that Nephros has a diversified customer base across various industries. Their ultrafiltration products are particularly relevant in the medical sector, where water purity is critical for patient care. Additionally, their water filters are designed to enhance the taste and odor of water, making them suitable for commercial and hospitality markets. With a growing emphasis on water quality and safety, Nephros is well-positioned to capitalize on the increasing demand for its products.
Examining the
To achieve this forecast, Nephros will need to continue executing on its growth strategy, expanding its customer base, and increasing its market share in the water treatment industry. The companys ability to innovate and adapt to changing market conditions will be crucial in driving its future success. With its strong product portfolio and diversified customer base, Nephros is well-positioned to capitalize on the growing demand for water treatment solutions, potentially driving its stock price higher in the coming months.
Additional Sources for NEPH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
NEPH Stock Overview
Market Cap in USD | 40m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Household Appliances |
IPO / Inception | 2004-09-21 |
NEPH Stock Ratings
Growth Rating | -40.3 |
Fundamental | 66.2 |
Dividend Rating | 0.0 |
Rel. Strength | 94.7 |
Analysts | 4.5 of 5 |
Fair Price Momentum | 3.92 USD |
Fair Price DCF | 0.88 USD |
NEPH Dividends
Currently no dividends paidNEPH Growth Ratios
Growth Correlation 3m | 88.6% |
Growth Correlation 12m | 13.6% |
Growth Correlation 5y | -58.9% |
CAGR 5y | -13.77% |
CAGR/Max DD 5y | -0.15 |
Sharpe Ratio 12m | -0.06 |
Alpha | 87.91 |
Beta | -0.761 |
Volatility | 63.60% |
Current Volume | 49.9k |
Average Volume 20d | 52.2k |
As of June 30, 2025, the stock is trading at USD 3.86 with a total of 49,943 shares traded.
Over the past week, the price has changed by -10.02%, over one month by +46.77%, over three months by +124.42% and over the past year by +82.94%.
Yes, based on ValueRay´s Fundamental Analyses, Nephros (NASDAQ:NEPH) is currently (June 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 66.22 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NEPH is around 3.92 USD . This means that NEPH is currently overvalued and has a potential downside of 1.55%.
Nephros has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy NEPH.
- Strong Buy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, NEPH Nephros will be worth about 4.2 in June 2026. The stock is currently trading at 3.86. This means that the stock has a potential upside of +9.59%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 4.8 | 23.1% |
Analysts Target Price | 4.8 | 23.1% |
ValueRay Target Price | 4.2 | 9.6% |